APA (7th ed.) Citation

F, A., C, B., DG, F., M, C., M, N., K, B., . . . GP, D. (2022). Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis. American journal of respiratory and critical care medicine, 206(12), 1463. https://doi.org/10.1164/rccm.202010-3832OC

Chicago Style (17th ed.) Citation

F, Ahangari, et al. "Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis." American Journal of Respiratory and Critical Care Medicine 206, no. 12 (2022): 1463. https://doi.org/10.1164/rccm.202010-3832OC.

MLA (9th ed.) Citation

F, Ahangari, et al. "Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis." American Journal of Respiratory and Critical Care Medicine, vol. 206, no. 12, 2022, p. 1463, https://doi.org/10.1164/rccm.202010-3832OC.